$RHHBY News Article - Genentech's Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer
https://marketwirenews.com/news-releases/gene...22929.html